Rate My Professor Nevin John

Dr Nevin John is a clinician-researcher affiliated with Monash University’s School of Clinical Sciences at Monash Health in the Faculty of Medicine, Nursing and Health Sciences. He earned his MBBS from the University of Adelaide in 2009 and a PhD in Neurosciences from University College London in 2021, focusing on MRI markers of brain metabolism in multiple sclerosis to understand mechanisms of injury and disability. Appointed as a Research Fellow in the Department of Medicine, he concurrently serves as Consultant Neurologist and Multiple Sclerosis specialist at Monash Health since 2021, assuming the role of head of the MS service in January 2022. In this capacity, he leads clinical care for over 1,500 patients with neuroinflammatory disorders across southeastern Victoria and acts as clinical lead for the MS group.

John’s research specializations encompass multiple sclerosis epidemiology—including geospatial analyses, risk factors, comorbidities, and their effects on disease outcomes—alongside advanced neuroimaging (MRI and optical coherence tomography), pregnancy-related changes in MS, and biomarkers for neuroinflammatory conditions such as adult-onset leukodystrophy. He is site primary investigator for the international MSBase registry and contributes to clinical trial design. Notable grants include the NHMRC Ideas Grant (ID 2037776, $1,359,383) for investigating pregnancy’s impact on the MS brain, MRFF grant (2024553, $2,000,000) exploring Epstein-Barr virus’s role in MS pathogenesis via OCCAMS, and MRFF (2032017, $1,498,776) for a pilot intervention enhancing bone health and muscle strength in MS patients. Key publications feature co-authorship in “Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1 and 2” (Medical Journal of Australia, 2025), “Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years” (Journal of Neurology, Neurosurgery & Psychiatry, 2025), and “Estimation of Transition Probabilities from a Large Cohort (>6000) of Australians Living with Multiple Sclerosis” (PharmacoEconomics, 2025). His work advances understanding and management of MS, supported by collaborations in international MS research networks.